-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, I0xGKmG8lAOk1/z/GnUDgnnGh4lW2svjJPRtTk1BE8woVqbXM3z5pYSU9YkrOEwh ZiQ2EK6WrapnuzDPtaCD8g== 0001157523-09-004676.txt : 20090630 0001157523-09-004676.hdr.sgml : 20090630 20090630165809 ACCESSION NUMBER: 0001157523-09-004676 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20090630 FILED AS OF DATE: 20090630 DATE AS OF CHANGE: 20090630 FILER: COMPANY DATA: COMPANY CONFORMED NAME: TARO PHARMACEUTICAL INDUSTRIES LTD CENTRAL INDEX KEY: 0000906338 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-22286 FILM NUMBER: 09919754 BUSINESS ADDRESS: STREET 1: 14 HAKTOR ST CITY: HAIFA BAY STATE: L3 ZIP: 26110 BUSINESS PHONE: 9143459001 MAIL ADDRESS: STREET 1: THREE SKYLINE DR CITY: HAWTHORNE STATE: NY ZIP: 10532 FORMER COMPANY: FORMER CONFORMED NAME: TARO VIT INDUSTRIES LTD /ISRAEL/ DATE OF NAME CHANGE: 19930601 6-K 1 a5998110.txt TARO PHARMACEUTICAL INDUSTRIES LTD. 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June, 2009 Commission File Number 000-22286 Taro Pharmaceutical Industries Ltd. (Translation of registrant's name into English) Italy House, Euro Park, Yakum 60972, Israel (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F |X| Form 40-F |_| Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____ Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes |_| No |X| If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-_____. The Company is filing the attached Statement of Cash Flows for the first quarter 2009 in order to supplement its Form 6-K report filed on May 26, 2009. The Company cautions that the financial information herein does not constitute complete financial information, has not been reviewed by the Company's independent auditors and is subject to possible change. As of the date of this filing, the Company is not in a position to complete and file its financial statements for the year ended December 31, 2006, as previously expected. The Company believes that it has made substantial progress in resolving the few remaining issues with respect to the accounting for the restatement years. The Company continues to work diligently with its independent auditors to resolve these outstanding issues and complete the financial statements and the audit for the year 2006 and the restated prior periods. After finalization of the 2006 financial statements, the Company will turn its attention to completing its 2007 and 2008 financial statements. - Statement of Cash Flows follows -
TARO PHARMACEUTICAL INDUSTRIES LTD. SUMMARY CONSOLIDATED STATEMENT OF CASH FLOWS (US Dollars in thousands) Unaudited and Unreviewed ------------------------ Three Months Ended March 31, 2009 ------------------------ Operating Activities: Net Income $ 11,104 Adjustments Required to Reconcile Net Income to Net Cash Provided by (Used in) Operating Activities: Depreciation and Amortization 4,791 Stock Based Compensation 59 Increase in Fair Value of Long-term Derivative Instruments 4,692 Increase in Fair Value of Short-term Derivative Instruments 924 Increase in Long-term Debt due to Currency Fluctuations (5,636) Increase in Trade Receivables (5,445) Decrease in Other Receivables and Tax Assets (2,836) Decrease in Inventories 3,552 Foreign Exchange Effect of Intercompany Balances (2,755) Decrease in Trade and Other Payables and Accruals (3,262) ------------------------ Net Cash Provided by Operating Activities 5,188 Investing Activities: Purchase of Plant, Property & Equipment (699) Investment in Other Intangible Assets (39) ------------------------ Net Cash (Used in) Investing Activities (738) Financing Activities: Repayments of Short-term Bank Debt, net (196) Repayments of Long-term Loans (1,304) ------------------------ Net Cash (Used in) Financing Activities (1,500) Effect of Exchange Rate Changes (247) ------------------------ Net Increase in Cash 2,703 Cash at Beginning of Period 78,052 ------------------------ Cash at End of Period $ 80,755 ========================
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: June 30, 2009 TARO PHARMACEUTICAL INDUSTRIES LTD. By: /s/ Ron Kolker ----------------- Name: Ron Kolker Title: Senior Vice President, Chief Financial Officer -----END PRIVACY-ENHANCED MESSAGE-----